![Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]](/content/dam/novonordisk/esperoctpro/global/esperoct-logo.png){kind=logo}
In a Phase 3 pivotal trial, Esperoct® was shown to be effective in controlling 97% of bleeds with 1-2 infusions.1,a
BLEED TREATMENT WHEN THEY NEED IT
BLEED TREATMENT WHEN THEY NEED IT
Prepare your adult and adolescent hemophilia A patients for the unexpected with effective control of bleeding episodes.
BLEED CONTROL THEY CAN COUNT ON
PREPARE THEM FOR THE UNEXPECTED
aIn a phase 3, open-label study, safety, pharmacokinetics, and efficacy of Esperoct® were evaluated in PTPs aged ≥12 years with severe hemophilia A; 175 received routine prophylaxis (50 IU/kg every 4 days) and 12 adults elected to be treated on demand during the main phase. Treatment-requiring bleeds were reported by patients through diaries. 12 patients treated on demand reported 532 of 968 bleeds in the main phase.1
DOSING THAT KEEPS THINGS SIMPLE
bAdditional dose can be administered every 24 hours for major or life-threatening bleeding.
Esperoct® was shown to provide effective perioperative bleed control.
Trial prescription program.
Qualifying patients can receive a trial prescription for Esperoct®. To learn more about our trial prescription program, please call 1-844-668-6732 to speak with a NovoSecure™ Specialist.
